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 A distinct group of inherited metabolic disorders 
caused by a defect of the enzymes involved in 
glycogen synthesis, degradation, or regulation 
are classified under the umbrella term of 
glycogen storage diseases (GSDs). Several studies 
have reported the overall GSD incidence to be 
approximately 1 case per 20000-43000 live births.1
 Glycogen is the storage form of glucose and the 
chief source of non-oxidative glucose disposal. It is 
most copiously present in the liver and muscle cells, 
in addition smaller amounts are present in brain, 
heart, kidney, adipose tissue and erythrocytes. It 
serves to maintain glucose homeostasis in the liver 
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whereas provides substrates for the adenosine 
triphosphate (ATP) in the muscles.2
 The GSDs can be classified on the basis of organ 
affected and the enzyme deficiency involved. 
On the basis of target organ involved GSDs are 
comprised of three broad groups including; hepatic 
type of GSDs, muscles type of GSDs and the group 
affecting both liver and muscles. Each group 
has several different types; caused by defect of a 
different enzyme or a transporter, which is encoded 
by a different gene (Table-I).
 From a clinician’s perspective the hepatic group 
of GSDs often has an easily recognizable clinical 
phenotype usually apparent as doll-like facies, 
failure to thrive/short stature, hepatomegaly 
and the biochemical features of fasting ketotic 
hypoglycemia, lactic academia, raised alanine 
transaminase with or without hypertriglyceridemia 
and hyper-uricemia.3 The muscular group on the 
other end presents with neuromuscular symptoms, 
weakness and cardiomopathy.
 In Pakistan the conventional diagnostic approach 
towards hepatic types of GSDs includes recognition 
of clinical symptoms followed by biochemical work 
up and ultimately the more invasive liver biopsy to 
reveal features consistent with fatty change, nuclear 
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ABSTRACT
The glycogen storage diseases (GSDs) are a group of inherited metabolic disorders that result from a 
defect in any one of several enzymes required for either glycogen synthesis or glycogen degradation. The 
traditional diagnostic approach is based on the invasive hepatic or muscle biopsies, which are neither 
cost effective nor convenient. Molecular (gene testing) has emerged over the course of past few years 
as a robust alternative diagnostic tool, which not only confirms the diagnosis of GSDs but also clearly 
differentiates the types of GSDs allowing the initiation of the type-specific appropriate treatment for the 
particular type of GSDs. The aim of this update is to highlight the limitations of undertaking a liver biopsy 
for the diagnosis of GSDs; and to further describe the pros of the molecular testing for better patient 
centered care. 
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hyper-glycogenation and fibrosis. Additional 
electron microscopy and enzyme studies on the 
liver tissue are required to specify the type of GSDs. 
Neither the electron microscopy nor the enzyme 
assays for GSDs are locally available, which 
compromises the diagnostic yield of liver biopsy for 
diagnosing GSD in local setting. The liver biopsy 
has the following limitations, some of which are 
specific to Pakistan:
• Controversial diagnostic accuracy for GSDs with 
lack of specificity based on light microscopy 
only.
• The procedure is invasive with serious 
complications including pain, hemorrhage, bile 
peritonitis, penetration of abdominal viscera, 
pneumothorax, and even death.4
• The high cost including multiple clinic visits, 
anesthesia reviews and procedure cost.  
• Lack of centers with trained staff with sufficient 
experience for performing liver biopsy, further 
adds to the constraints especially for patients in 
smaller cities with limited technical expertise 
available.
• Usually 30–40 mg of tissue or four cores of hepatic 
tissue including about 15 mg of snap-frozen 
hepatic tissue in liquid nitrogen is required 
for all the studies necessary including light 
microscopy, electron microscopy and enzymes 
analysis to make a definitive diagnosis.5
• Specialized laboratories offering enzyme studies 
for hepatic GSDs are not available in Pakistan 
thus liver tissues are needed to be out-sourced 
to overseas laboratories in completely frozen 
condition with very vigilant temperature control, 
which is extremely challenging and chances of 
losing the precious hepatic tissue collected after 
an invasive procedure are very high.
• Electron microscopy on the hepatic tissue, 
which is required for the diagnosis of GSDs is 
not readily available at most diagnostic centers 
in the country owing to its high cost. 
• The treatment is aimed at specific type of GSDs, 
which is not possible based on only histo-
pathological findings of hepatic tissue on light 
microscopy without the enzyme testing, which 
is not available in Pakistan.
 On the other molecular testing, which was 
previously only performed to supplement enzyme 
activity analysis and confirm equivocal results has 
now become the principal diagnostic tool for GSDs.6 
The distinct advantages of the molecular approach 
are as follows:
• Non-invasive compared to the liver biopsy.
• High diagnostic accuracy as molecular methods 
minimize false positive test results by targeting 
the specific gene of interest.
• Molecular testing clearly differentiates between 
different types of GSDs allowing physicians 
to initiate specific type-based treatment of 
GSDs and organizing the specific type-based 
surveillance plan, which varies significantly for 
various GSDs.
• Ease of sample transportation to the laboratory 
without vigilant temperature control. 
• Automated analyzers are available and a 
single trained pathologist can report numerous 
samples.
• Short turnaround times, which is 48 hours.
• Cost-effective, as the cost of next-generation 
sequencing (NGS) allowing analysis of multiple 
genes in a single DNA sample is around $278.7 
It is roughly half the cost of a liver biopsy 
procedure followed by light microscopy, 
electron microscopy and enzyme testing. 
Although, the liver biopsy procedure followed 
by light microscopy in public sector hospitals is 
provided free to patients, but the indirect and 
direct cost is actually borne by the state, which 
includes the liver biopsy procedure performed 
by a physician/pathologist, medical supplies 
Table-I: Classification of GSDs and 
their associated enzyme deficiencies.
GSDs with Hepatic involvement
Types  Enzymes/Transport Defect Genes
GSD 0 Glycogen Synthase GYS2
GSD Ia Glucose-6-phosphotase G6PC
GSD Ib Glucose-6-phosphotase transporter SLC37A4
GSD VI Glycogen phosphorylase (liver) PYGL
GSD IXa Phosphorylase kinase (α subunit) PHKA2
GSD IXb Phosphorylase kinase (β subunit) PHKB
GSD IXc Phosphorylase kinase (γ subunit) PHKG2
GSD XI Glucose transporter-2 SLC2A2
GSDs with Neuromuscular involvement
Types  Enzymes/Transport Defect Genes
GSD IIa α-1,4 glucosidase GAA
GSD IIb LAMP-2 protein LAMP2
GSD V Glycogen phosphorylase (muscle) PYGM
GSD VII Phosphofructokinase  PFKM
GSD IXd Phosphorylase kinase (δ subunit) CLAM1
GSDs with both Hepatic & Neuromuscular involvement
Types  Enzymes/Transport Defect Genes
GSD III Amylo-1,6-glucosidase AGL
GSD IV Amylo-1,4 →1,6 transglucosylase  GBE1
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involved in liver biopsy procedure, anesthesia 
coverage for the procedure, day care admission 
cost and the clinical care needed following an 
invasive procedure.
• Provision of reliable prenatal diagnosis and 
carrier testing by offering targeted familial 
variant testing to at-risk couples and carrier 
testing for family members. 
 Early diagnosis of GSDs is imperative for 
initiation of appropriate treatment and achieving 
better prognosis. Owing to the nonspecific clinical 
presentation of GSDs and the lack of specific 
biomarkers to differentiate various types of GSD, 
NGS has become the first line diagnostic tool for 
the evaluation of GSD. NGS depends on massive 
molecular parallelization and allows analyzing 
multiple genes at the same time in a single DNA 
sample, it is a rapid and a much cost-effective way 
of not only diagnosing GSD but also differentiate 
different types of GSDs in absence of the invasive 
procedure of liver biopsy.
 In context of NGS instrumentation availability, 
a wide variety exists e.g. MiniSeq and Miseq from 
Illumina, Ion Torrent from Life Technologies 
Thermo Fischer Scientific and MinION from Oxford 
Nanopore etc. These differ primarily in terms of 
cost, capacity, principle chemistry and read length, 
DNA library preparation and run time. On the 
basis of feasibility, the Illumina MiSeq is the most 
popular sequencer due to its relatively low cost, 
significantly low error rate and capacity to deliver 
the moderate throughput required by most centers.7
 From a local perspective, measurement of 
enzyme activity suffers from logistic issues and is 
technically more challenging alongside a dearth of 
laboratory expertise. Furthermore, enzyme analysis 
is usually not reliable in detecting heterozygous 
carriers of a disease. These testing modalities are 
often very laborious, time consuming and require 
a pre-selection by clinical phenotype for targeting 
the specific enzyme.8 On the contrary, NGS has now 
become the gold standard to confirm a suspected 
diagnosis of GSD owing to its comparatively low 
cost, rapid analysis time and availability of less 
technically demanding automated platforms. 
Enzyme analysis on hepatic tissue is only needed 
in certain cases when there are unclear molecular 
results like variants of uncertain significance found 
on gene testing.
 In line with the best practices, the undertaking of 
molecular testing for suspected cases with GSDs, 
by outsourcing the samples abroad to accredited 
laboratories has been a standard practice at our 
institute. For this purpose, the extracted DNA 
samples from peripheral (whole) blood specimen is 
outsourced for NGS based GSDs panels, with ease 
of transportation at room temperature.
 The capacity and capability to perform molecular 
testing using NGS is available in Pakistan. NGS 
equipment and proficient molecular pathologists 
and molecular geneticists are present at few 
centers locally, but molecular testing for GSDs is 
currently not offered in the country. In most clinical 
settings, the pediatricians and pediatric metabolic 
geneticists outsource NGS molecular testing to 
various accredited centers abroad, offering GSDs 
panels. However, the expertise of local molecular 
pathologists and molecular geneticists can be easily 
nurtured in this respect; and the widespread use of 
molecular testing of GSD can be achieved with its 
added distinct advantages. 
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